Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.12.19
Views: 261
Rating:

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA

Dr Mikkael Sekeres speaks to ecancer at the ASH 2019 meeting in Orlando about updated results from a phase 1b study evaluating glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML.

He explains that glasdegib is FDA approved in combination with low-dose cytarabine but that now this is the first time it is being used in combination with azacitidine, a drug that is far more commonly used.

Dr Sekeres reports that the response rates seen were comparable if not better to the combination of glasdegib and cytarabine.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

18.02.20

no rating
Epidemiology of cancer in India

follow us

Biosimilar Medicines Core Principles and Communication


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation